Objective To determine if newborn screening (NBS) programs for congenital hypothyroidism in the US use thyroidstimulating hormone (TSH) cutoffs that are age adjusted to account for the physiologic 4-fold reduction in TSH concentrations over the first few days of life.
Conclusions There is variation in NBS practices for screening for congenital hypothyroidism across the US, and many programs do not adjust the TSH cutoff beyond the first 2 days of life. Samples are processed when received from older infants, often to retest borderline initial results. This approach will miss congenital hypothyroidism in infants with persistent mild TSH elevations. We recommend that all NBS programs provide age-adjusted TSH cutoffs, and suggest developing a standard approach to screening for congenital hypothyroidism in the US. (J Pediatr 2018; 192:204-8) .
C ongenital hypothyroidism has an incidence of approximately 1 in 2000 to 4000 births 1 and more than 1400 of the 3.4 million infants born in the US are diagnosed with congenital hypothyroidism annually. 2 Before the universal implementation of newborn screening (NBS), congenital hypothyroidism was a leading cause of intellectual disability. 2 The prevalence of congenital hypothyroidism has also increased with the implementation of universal screening, demonstrating detection of milder congenital hypothyroidism that was not associated with severe symptomatic intellectual disability. 3 The critical role of thyroid hormone in normal development and growth is supported by the positive effect of early identification and treatment of congenital hypothyroidism on neurodevelopmental outcomes. 4, 5 Even when congenital hypothyroidism is identified early, disease severity at the time of diagnosis and the time to normalization of thyroid-stimulating hormone (TSH) may affect cognitive outcome. 6, 7 Persistent moderate increases in TSH concentrations can be seen in children without severe congenital hypothyroidism. This cohort includes infants with thyroid hypoplasia, hemiagenesis, ectopy, or normally appearing thyroid glands that may ultimately develop into a goiter secondary to disorders involving thyroid dyshormonogenesis (eg, iodine organification defects, Pendred syndrome, defective thyroglobulin synthesis, a defective sodium-iodine symporter, pseudohypoparathyroidism, or trisomy 21). 8 The early detection of severe congenital hypothyroidism before the development of symptoms can significantly reduce the likelihood of developing intellectual disability. 9 The effect of untreated isolated mild hyperthyrotropinemia is likely to be more subtle, and it remains controversial whether very mild persistent increases in TSH concentrations have adverse neurodevelopmental consequences. At the lower end of this spectrum, infants with whole blood TSH concentrations of up to 15 mU/L do not have detectable reductions in intelligence quotient 10 or psychomotor development. 11 In studies showing neurocognitive effects of mild hyperthyrotropinemia, confounding effects of maternal iodine deficiency on fetal development may reduce the generalizability of any benefit of treatment to iodinesufficient populations. 12, 13 A large study in Australia describing cognitive outcomes in children with mild elevations in TSH concentrations on NBS describes an association between impairment in cognitive outcome with increases in TSH concentration, but this may also be confounded by maternal iodine status.
14 Consequently, guidelines from the European Society for Pediatric Endocrinology recommend observing mild increases in venous TSH concentrations for up to 3-4 NBS Newborn screening T4 Thyroxine TSH Thyroid-stimulating hormone weeks before considering initiating treatment. 15 Once treatment is initiated, close follow-up is advised and reevaluation at 3 years of age is advised if imaging does not show a permanent form of congenital hypothyroidism or if there is no increase in TSH concentration above 10 mU/L after 1 year of age. 16, 17 After delivery, serum TSH concentrations in a term infant increase to a mean of approximately 80 mU/L at 30 minutes of life and then decrease rapidly over the next 2 days 18 ; the TSH concentration is usually less than 10 mU/L by 1 week of life, and is typically within the normal range for children and adults by 2 weeks of age. 19 This normal transitional pattern is the basis for establishing age-based specific norms for newborn TSH concentrations within the first week of life. Although higher TSH concentrations are considered normal during the first 48-72 hours of life, similar levels outside of this time frame may be a sign of underlying thyroid dysfunction. 19, 20 Recognizing this, guidelines from the American Academy of Pediatrics recommend that "blood be collected when the infant is between 2 and 4 days of age," 2 and guidelines from the European Society for Pediatric Endocrinology state that "the best 'window' for testing is 48 to 72 hours of age." 15 Thus, if a NBS sample is collected outside of the recommended timeframe, an infant with persistent mild increased TSH concentrations would be misclassified as having a normal result if reference ranges do not account for the age of the infant at the time of sample collection.
The aims of this study were to describe the approaches to NBS for congenital hypothyroidism across the US, and to determine if these screening algorithms use age-specific cutoffs for TSH concentrations in term infants.
Methods
All NBS programs in the US were included in this study. Laboratories and departments of public health were contacted by phone initially, or email if the personnel were not available. Where possible, information was supported by review of www.newsteps.org or published protocols.
Data were collected using semistructured interviews inquiring about modality of testing, recommended age of testing, age limits of NBS, TSH cutoffs (including cutoff for action), and protocols for handling abnormal results. Only protocols pertaining to term infants were included. All NBS programs in the US report screening TSH results as serum concentrations. Because most programs assume an average hematocrit of 50%-55% in newborns, whole blood TSH concentrations are one-half the equivalent serum concentration. When comparing our results with studies that report whole blood TSH concentrations, whole blood values were multiplied by 2 to calculate comparable serum TSH concentrations.
Because patient information was not collected or analyzed, the Institutional Review Board at The Children's Hospital of Philadelphia deemed this study exempt from review.
Statistical Analyses
Centers were categorized according to testing protocol (primary TSH with backup thyroxine [T4], combined primary TSH and T4, primary T4 with backup TSH), whether or not a routine repeat NBS is performed, age-specific TSH cutoffs, how many times TSH reference values are age adjusted, whether confirmatory serum or repeat NBS are recommended or accepted for borderline elevated TSH, and the age limit at which repeat NBS are no longer accepted. In programs that used initial T4 testing, the TSH cutoffs were used for analysis. T4 cutoffs were not analyzed. Only TSH levels beyond the first 24 hours of life (ie, the recommended screening period) were analyzed.
Analyses were conducted in SPSS version 22.0 (IBM, Armonk, New York). Figures were generated using Prism 5.0 (GraphPad Software Inc, La Jolla, California) and Adobe Illustrator (Adobe Systems Inc, San Jose, California).
Results
All 51 NBS programs in the US were contacted and representatives from 50 programs completed semistructured interview. Information regarding the process in the remaining program was available online.
Among healthy, term infants, the NBS collection is recommended in the first 1-3 days of life in all programs. Despite this recommendation, 50 of the 51 programs will process initial NBS samples collected beyond the first 4 days of life. One program recommends that physicians measure serum TSH concentrations (rather than process a late NBS) if the initial window for NBS is missed; 14 programs (27%) perform a routine second NBS for all newborns between 1 and 6 weeks of life.
Twenty-two programs (43%) measure primary TSH concentration. Of these, 6 subsequently measure total T4 concentrations in abnormal samples and 16 (31%) have algorithms based solely on TSH measurements. Twenty programs (39%) measure primary T4 and measure TSH concentrations only if T4 is abnormal. Nine programs (18%) measure both TSH and T4 concentrations in all newborns (Figure 1) . All programs have a TSH level that triggers immediate clinical referral and serum thyroid function testing.
For borderline elevated TSH concentrations (defined as TSH concentrations above the cutoff for normal results but below the cutoff for recommendation of urgent serum testing), 9 programs recommend obtaining serum thyroid function testing. These 9 programs do not recommend repeat NBS. Fourteen programs perform routine repeat NBS (which includes TSH) for all infants and, thus, no additional testing is recommended for borderline increased TSH. Eight of these programs use the same TSH cutoff for the initial and repeat NBS despite the infant being older at the time of repeat testing.
In 28 programs, repeat NBS are requested for borderline increased TSH concentrations. Of these, 12 measure only TSH concentrations on the repeat specimen. In these programs, the median TSH concentration above which urgent serum testing is recommended instead of repeat NBS is 50 mU/L (IQR, 50-60). In the other 16 of 28 programs that request repeat NBS, there are a combination of primary TSH with reflex to T4 and Volume 192 • January 2018 primary T4 with reflex to TSH testing. These programs have varied algorithms for referral and incorporate extremely low T4 concentrations as triggers for confirmatory serum testing.
TSH cutoffs were available from 49 of the 50 programs that accept and process thyroid testing on NBS received beyond the first 72 hours of life. Of these, 24 do not adjust the TSH cutoff according to the age of the infant. In these programs, the TSH concentration for an abnormal test (after 24 hours of life) ranges from 20 to 40 mU/L with a median of 25 mU/L (IQR, 20-30), regardless of the age of infant at the time of the test. Additionally, each program has a cutoff value above which immediate treatment and or referral to endocrinology is recommended (median, 50 mU/L; IQR, 40-60). The reported upper limit of normal for TSH concentrations on NBS according to the infant's age for each program is shown in Figures 2 and 3 . This figure demonstrates that, when NBS tests are performed outside of the first few days of life, TSH concentration cutoffs far higher than the age-appropriate range and the findings may be reported as normal in many programs.
Included in these 24 programs that do not adjust TSH concentration cutoffs according to the infant's age are 16 programs that request repeat NBS (rather than serum testing) for borderline increased TSH. Thus, the cutoff for TSH concentrations to be reported as abnormal in these 16 programs for the repeated test in an older infant is the same as for those within the first 3 days of life. Similarly, 8 of the 14 programs that perform routine second NBS for all infants do not adjust the TSH cutoff concentration for the second test.
Discussion
There is variation in practice among NBS programs across the US in the approach to screening for congenital hypothyroidism.
The key finding of this study is that many programs do not adjust the reported TSH cutoffs according to the infant's age, despite adopting protocols that may require repeat NBS TSH measurements outside of the age for which the cutoffs were established. In programs that adjust TSH cutoffs according to age, most do not adjust beyond day 3 of life, despite accepting samples up to and beyond 1 month of age.
Based on the data presented in this study, an infant with a serum TSH concentration of 24 mU/L will be incorrectly reported as "normal" in 28 programs if the sample was collected and run on a NBS platform on day of life 4, and 21 programs on day of life 7. Only 4 programs would flag a serum TSH concentration of 14 mU/L on day 10 of life as abnormal. This variance would affect infants with delayed initial NBS and infants with a recommended repeat NBS submitted because of a borderline elevated TSH on the initial NBS. Although infants with normal thyroid function have a 4-fold decrease in TSH concentrations between the first and the fourth days of life, 8 this may not fall to normal ranges in children with mild persistent congenital hypothyroidism. 21, 22 NBS protocols that do not apply age-specific TSH cutoff concentrations will not identify these infants.
There is active discussion surrounding the cost to benefit ratio to lowering the TSH cutoffs for NBS. In Greece, a lowering of the whole blood TSH cutoff for recall at days 3-5 from 20 to 10 mU/L (ie, serum TSH concentration from 40 to 20 mU/L) increased the recall rate from 0.12% to 1.20%, and more than 70% of the additional patients diagnosed with congenital hypothyroidism after this change were found to have permanent disease. 22 Similar changes to the TSH cutoff in Quebec did not identify additional infants with severe congenital hypothyroidism, but more than 70% of additional infants identified had permanent primary hypothyroidism. 23 Although any lowering of TSH cutoffs increases the recall rate, increases cost, and may increase parental anxiety, approximately one-third of infants with screening whole blood TSH concentrations between 16 and 20 mU/L (ie, between a serum TSH concentration of 32 and 40 mU/L) have persistent hypothyroidism. 21, 22 However, it is not known what the effect of applying age-appropriate TSH cutoffs to NBS samples collected outside the age window for which the normative data were established would be on recall rate.
The main strengths of this study are that it is a comprehensive review of NBS protocols for congenital hypothyroidism screening in healthy, term infants older than 24 hours in the US, and it identifies a correctable shortfall in the current approach to NBS in several states. Many programs use complex algorithms for identifying children with congenital hypothyroidism and assess both TSH and T4; nonetheless, absent or insufficient age adjustment of TSH cutoffs on NBS seems to be a common issue, regardless of which algorithm is used. In an effort to avoid bias, or an exaggeration of the data, we used the lowest TSH cutoffs described and may have slightly underestimated the risk. The limitation of this study is that we were unable to determine the direct clinical impact of these variable approaches to NBS in the US. Without systematically following up patients who pass NBS according to current state-specific algorithms or data on the diagnosis of hypothyroidism within the first few years of life, it was not possible to study the prevalence of missed persistent congenital hypothyroidism in this population. It would also be difficult to prospectively study this by following infants with persistent hyperthyrotropinemia to assess potential negative neurocognitive outcomes, as current guidelines 15 indicate that it would not be appropriate to withhold levothyroxine treatment in this context.
In conclusion, we have demonstrated significant variation in the approach to NBS for congenital hypothyroidism across the US. We have shown that high TSH cutoffs, validated for first 3 days of life, are often used to assess thyroid function in infants older than 72 hours of life. We recommend that all programs consider using age-adjusted TSH cutoffs, given that current approaches may miss children with mild persistent congenital hypothyroidism. We also suggest that NBS screening for congenital hypothyroidism be reviewed on a national level so that a more standardized approach may be adopted across the US, although budget implications of any change would have to be approved at the state level. ■ TSH cutoff (mU/L) Figure 3 . Range of TSH cutoffs for all NBS programs at various days of life. The bar in each box represents the median cutoff of available programs with the box representing the interquartile range. Two states use combined primary TSH and T4 to determine whether or not to repeat the NBS and, thus, were excluded from this figure.
